Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TROV

Cardiff Oncology (TROV) Stock Price, News & Analysis

Cardiff Oncology logo

About Cardiff Oncology Stock (NASDAQ:TROV)

Advanced Chart

Key Stats

Today's Range
$2.72
$2.87
50-Day Range
$1.19
$24.71
52-Week Range
$0.70
$3.46
Volume
693,985 shs
Average Volume
648,892 shs
Market Capitalization
$31.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Receive TROV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

TROV Stock News Headlines

Cardiff Oncology announces second patent for onvansertib combination
U.S. Stock Market Now on Verge of Collapse
The last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost 80% of their wealth in real terms. But before you touch any of your holdings – or buy anything – please review my latest warning about the U.S. stock market. It's free to watch.
William Blair Keeps Their Buy Rating on Cardiff Oncology (CRDF)
See More Headlines

TROV Stock Analysis - Frequently Asked Questions

Cardiff Oncology, Inc. (NASDAQ:TROV) announced its earnings results on Thursday, February, 27th. The medical research company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.14. The medical research company earned $0.09 million during the quarter. Cardiff Oncology had a negative net margin of 3,688.31% and a negative trailing twelve-month return on equity of 202.00%.

Cardiff Oncology's stock reverse split on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include XOMA (XOMA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
2/27/2020
Today
5/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TROV
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-16,410,000.00
Net Margins
-3,688.31%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$250,000.00
Price / Cash Flow
N/A
Book Value
$0.94 per share
Price / Book
3.00

Miscellaneous

Free Float
N/A
Market Cap
$31.05 million
Optionable
Not Optionable
Beta
1.04

This page (NASDAQ:TROV) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners